Compare NIO Inc. (NIO) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NIO Inc. vs Natera Inc. Common Stock — how do they compare? NIO Inc. trades at $3.4 (market cap $8.76B), while Natera Inc. Common Stock trades at $392.78 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 6.5× NIO Inc.'s market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, NIO Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold NIO Inc. for 81 Days and Natera Inc. Common Stock for 0 Days on average.
| NIO | NTRA | |
|---|---|---|
Market Cap | $8.76B | $57.03B |
Volume | 36,159,487 | 1,131,157 |
Sector | Consumer Cyclical | Health |
52-Week High | $7.42 | $425.64 |
52-Week Low | $3.37 | $179.42 |
Typical Hold Time | 81 Days | 0 Days |
Enterprise Value | $6.65B | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NIO trades at $3.56, up 2.59% today, but remains near 52-week lows amid a bearish technical trend. The company reported Q3 2026 deliveries up 25.4% and has beaten EPS estimates for three consecutive quarters, yet continues to post net losses with a -4.17% margin. A strategic battery-swap partnership with Geely aims to expand network utilization, valued at $2.38 billion, though it initially weighed on the stock. Revenue growth is robust, reaching $87.49 billion in 2025, but profitability challenges and high debt levels persist.
The outlook is mixed: analyst consensus is bullish with a $6.23 price target, but execution risks in a competitive EV market and persistent cash burn pose significant hurdles. Upside depends on margin improvement and successful scaling of the battery-swap ecosystem, while downside risks include prolonged losses and industry price wars.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NIO Inc.
NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.
Read more on NIO →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
